B of A Securities analyst Jason Gerberry downgrades FibroGen (NASDAQ:FGEN) from Neutral to Underperform and lowers the price target from $4 to $2.
- Headlines
- B of A Securities Downgrades FibroGen to Underperform, Lowers Price Target to $2
B of A Securities Downgrades FibroGen to Underperform, Lowers Price Target to $2
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
20:22
StoneX market research director Matt Well: The Federal Reserve may pause for a while, possibly throughout the first quarter of next year, and then might only gradually lower interest rates occasionally as the Fed tries to refine its policy.
SNEX-1.67%
20:16
The Doubao APP ranks second in global monthly active users.
20:12
Song Zhiping: Now is a good time for mergers and acquisitions.
HSY-0.46%